iOmx Therapeutics AG, a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the appointment of Dr. Christine Rothe as Chief Development Officer. Dr. Rothe brings over 25 years of biopharma industry experience in research and drug discovery in various disease areas.
Dr. Christine Rothe joins iOmx Therapeutics from Pieris Pharmaceuticals, where she served as VP EarlyStage Project Leadership & Data Science. Prior to this, she was VP Discovery & Alliance Management with Pieris. She played a major role in shaping the drug discovery process and in advancing novel therapeutics in immunooncology and other disease areas from program inception towards the clinic. Dr.
Rothe began her industry career at MorphoSys, holding several positions in R&D and Alliance Management. In these positions, she led technology development and therapeutic antibody project teams. She received her Ph.D. in cell biology from the University of Regensburg.
I look forward to adding scientific knowledge and leadership experience to complement and further strengthen iOmx’ R&D capacity.
